Novartis boosts oncology with $3.9bn acquisition

01-11-2017

Novartis boosts oncology with $3.9bn acquisition

designer491 / iStockphoto.com

Swiss pharmaceutical company Novartis has bolstered its oncology portfolio with the acquisition of Advanced Accelerator Applications (AAA).


Novartis, mergers & acquisitions, Advanced Accelerator Applications, radiopharmaceutical, oncology, Lutathera 


LSIPR